JP2018538367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538367A5 JP2018538367A5 JP2018545568A JP2018545568A JP2018538367A5 JP 2018538367 A5 JP2018538367 A5 JP 2018538367A5 JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018538367 A5 JP2018538367 A5 JP 2018538367A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- treatment
- heart failure
- medicament
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 7
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 claims 2
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- PAEBEUZTAPIOIO-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea Chemical group O=C1N(C=2C=CC=CC=2)N(C)C(C(C)C)=C1NC(=O)NC1=CC=C(Cl)C=C1 PAEBEUZTAPIOIO-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259498P | 2015-11-24 | 2015-11-24 | |
| US62/259,498 | 2015-11-24 | ||
| PCT/US2016/063036 WO2017091496A1 (en) | 2015-11-24 | 2016-11-21 | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018538367A JP2018538367A (ja) | 2018-12-27 |
| JP2018538367A5 true JP2018538367A5 (OSRAM) | 2019-12-19 |
Family
ID=57544530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545568A Withdrawn JP2018538367A (ja) | 2015-11-24 | 2016-11-21 | ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180325869A1 (OSRAM) |
| EP (1) | EP3380091A1 (OSRAM) |
| JP (1) | JP2018538367A (OSRAM) |
| KR (1) | KR20180081528A (OSRAM) |
| CN (1) | CN108348479A (OSRAM) |
| AU (1) | AU2016359463A1 (OSRAM) |
| BR (1) | BR112018010155A8 (OSRAM) |
| CA (1) | CA3006291A1 (OSRAM) |
| EA (1) | EA201891007A1 (OSRAM) |
| IL (1) | IL259468A (OSRAM) |
| MX (1) | MX2018005756A (OSRAM) |
| SG (1) | SG11201803816RA (OSRAM) |
| WO (1) | WO2017091496A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102772801B1 (ko) | 2015-12-10 | 2025-02-24 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| CN110997661B (zh) | 2017-06-09 | 2023-03-31 | 百时美施贵宝公司 | 环丙基脲甲酰肽2受体和甲酰肽1受体激动剂 |
| US11186544B2 (en) | 2017-06-09 | 2021-11-30 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| MY204384A (en) | 2018-03-05 | 2024-08-27 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| US12281108B2 (en) | 2018-11-26 | 2025-04-22 | Bristol-Myers Squibb Company | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2225231B1 (en) * | 2007-12-18 | 2011-08-17 | Actelion Pharmaceuticals Ltd. | Aminotriazole derivatives as alx agonists |
| WO2012066488A2 (en) * | 2010-11-17 | 2012-05-24 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
| CN104284887B (zh) * | 2012-05-16 | 2016-06-22 | 埃科特莱茵药品有限公司 | 作为alx受体激动剂的经1-(对-甲苯基)环丙基取代的桥联螺[2.4]庚烷衍生物 |
| KR102772801B1 (ko) * | 2015-12-10 | 2025-02-24 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| MY204384A (en) * | 2018-03-05 | 2024-08-27 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
-
2016
- 2016-11-21 EP EP16810536.9A patent/EP3380091A1/en not_active Withdrawn
- 2016-11-21 EA EA201891007A patent/EA201891007A1/ru unknown
- 2016-11-21 JP JP2018545568A patent/JP2018538367A/ja not_active Withdrawn
- 2016-11-21 KR KR1020187014477A patent/KR20180081528A/ko not_active Withdrawn
- 2016-11-21 MX MX2018005756A patent/MX2018005756A/es unknown
- 2016-11-21 WO PCT/US2016/063036 patent/WO2017091496A1/en not_active Ceased
- 2016-11-21 SG SG11201803816RA patent/SG11201803816RA/en unknown
- 2016-11-21 CA CA3006291A patent/CA3006291A1/en not_active Abandoned
- 2016-11-21 AU AU2016359463A patent/AU2016359463A1/en not_active Abandoned
- 2016-11-21 CN CN201680068442.7A patent/CN108348479A/zh active Pending
- 2016-11-21 US US15/776,927 patent/US20180325869A1/en not_active Abandoned
- 2016-11-21 BR BR112018010155A patent/BR112018010155A8/pt not_active Application Discontinuation
-
2018
- 2018-05-17 IL IL259468A patent/IL259468A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538367A5 (OSRAM) | ||
| JP2020523327A5 (OSRAM) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| JP2016518337A5 (OSRAM) | ||
| JP2016034978A5 (OSRAM) | ||
| JP2016510326A5 (OSRAM) | ||
| EP4424328A3 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| EP4335418A3 (en) | Compositions and methods for treating pterygium | |
| JP2015508749A5 (OSRAM) | ||
| JP2018184433A5 (OSRAM) | ||
| JP2017532343A5 (OSRAM) | ||
| JP2017222722A5 (OSRAM) | ||
| JP2017519739A5 (OSRAM) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| RU2017145271A (ru) | Терапевтическое средство для фиброза | |
| JP2017517512A5 (OSRAM) | ||
| JP2015120685A5 (OSRAM) | ||
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| JP2019510079A5 (OSRAM) | ||
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| JP2013166781A5 (OSRAM) | ||
| CR20220096A (es) | Proteínas de fusión terapéuticas | |
| MX389330B (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| JP2013087119A5 (OSRAM) | ||
| JP2018513846A5 (OSRAM) |